Observational Study
Copyright ©The Author(s) 2023.
World J Gastroenterol. Dec 7, 2023; 29(45): 5962-5973
Published online Dec 7, 2023. doi: 10.3748/wjg.v29.i45.5962
Figure 1
Figure 1 Prevalence of metabolic dysfunction-associated fatty liver disease by muscle strength. A: The prevalence of metabolic dysfunction-associated fatty liver disease (MAFLD) in the total participants; B: the prevalence in men and women; C: the prevalence in different age groups. The prevalence of MAFLD was higher in the lower muscle strength quartile groups in total participants and age and sex groups. The prevalence was higher in the lowest muscle strength quartile (Q1) group than in the remaining groups (Q2–Q4) in both sexes and all age groups. A dose-response relationship between lower muscle strength quartile and MAFLD was also observed. Q: Quartile; MAFLD: Metabolic dysfunction-associated fatty liver disease.